A retrospective budget impact analysis of fidaxomicin treatment for Clostridioides difficile infections (CDI) in Germany.

IF 1.8 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-10-01 Epub Date: 2024-05-09 DOI:10.1080/14737167.2024.2352005

Ann-Cathrine Siefen, Melina Sophie Kurte, Anna Marie Bauer, Oliver A Cornely, Sebastian Wingen-Heimann, Florian Kron

{"title":"A retrospective budget impact analysis of fidaxomicin treatment for Clostridioides difficile infections (CDI) in Germany.","authors":"Ann-Cathrine Siefen, Melina Sophie Kurte, Anna Marie Bauer, Oliver A Cornely, Sebastian Wingen-Heimann, Florian Kron","doi":"10.1080/14737167.2024.2352005","DOIUrl":null,"url":null,"abstract":"Background: Clostridioides difficile is the most common cause of healthcare-associated diarrhea. Research suggests that treating C. difficile infections (CDI) with fidaxomicin (FDX) is more effective than vancomycin (VAN), with potential cost savings. The objective was to calculate the budget impact of FDX treatment compared to VAN from a German payer perspective.Research design and methods: The analysis used real-world data of patients discharged from University Hospital Cologne between Jan-01-2018 and Dec-31-2019. We identified recurrent and non-recurrent CDI cases and calculated direct treatment costs based on G-DRG flat rates. To calculate average costs per treatment and the budget impact, recurrence probabilities for VAN and FDX were taken from published evidence (28-day and 90-day scenarios).Results: Totally, 475 cases were analyzed, thereof 421 non-recurrent, causing mean costs of €32,901 per case (95% CI: 27.752-38.050). Thirty-two patients experienced a recurrence within 28 days, yielding mean costs of €10,952 (95% CI: 5.627-16.277) for their additional hospital stay. The resulting budget impact was €1,303 (95% CI: 670-1.937) in favor of FDX, ranging from €148.34 to €2,190.30 in scenario analyses.Conclusion: The analysis indicates FDX treatment can lead to cost savings compared to VAN. Future research should focus on specific patient groups, such as refractory CDI patients.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2024.2352005","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Clostridioides difficile is the most common cause of healthcare-associated diarrhea. Research suggests that treating C. difficile infections (CDI) with fidaxomicin (FDX) is more effective than vancomycin (VAN), with potential cost savings. The objective was to calculate the budget impact of FDX treatment compared to VAN from a German payer perspective.

Research design and methods: The analysis used real-world data of patients discharged from University Hospital Cologne between Jan-01-2018 and Dec-31-2019. We identified recurrent and non-recurrent CDI cases and calculated direct treatment costs based on G-DRG flat rates. To calculate average costs per treatment and the budget impact, recurrence probabilities for VAN and FDX were taken from published evidence (28-day and 90-day scenarios).

Results: Totally, 475 cases were analyzed, thereof 421 non-recurrent, causing mean costs of €32,901 per case (95% CI: 27.752-38.050). Thirty-two patients experienced a recurrence within 28 days, yielding mean costs of €10,952 (95% CI: 5.627-16.277) for their additional hospital stay. The resulting budget impact was €1,303 (95% CI: 670-1.937) in favor of FDX, ranging from €148.34 to €2,190.30 in scenario analyses.

Conclusion: The analysis indicates FDX treatment can lead to cost savings compared to VAN. Future research should focus on specific patient groups, such as refractory CDI patients.

查看原文本刊更多论文

德国治疗艰难梭菌感染 (CDI) 的菲达霉素预算影响回顾分析。

背景：艰难梭状芽孢杆菌是最常见的医源性腹泻病因。研究表明，用菲达霉素（FDX）治疗艰难梭菌感染（CDI）比万古霉素（VAN）更有效，并有可能节约成本。研究的目的是从德国支付方的角度计算 FDX 治疗与 VAN 相比对预算的影响：分析使用了科隆大学医院 2018 年 1 月 1 日至 2019 年 12 月 31 日期间出院患者的真实世界数据。我们确定了复发性和非复发性 CDI 病例，并根据 G-DRG 统一费率计算了直接治疗费用。为了计算每次治疗的平均成本和对预算的影响，我们从已发表的证据（28 天和 90 天方案）中提取了 VAN 和 FDX 的复发概率：共分析了 475 个病例，其中 421 例为非复发病例，每个病例的平均费用为 32,901 欧元（95% CI：27.752-38.050）。32名患者在28天内复发，平均住院费用为10,952欧元（95% CI：5,627-16,277）。由此产生的预算影响为 1,303 欧元（95% CI：670 - 1.937），有利于 FDX，在方案分析中，预算影响从 148.34 欧元到 2,190.30 欧元不等：分析表明，与 VAN 相比，FDX 治疗可节约成本。未来的研究应侧重于特定的患者群体，如难治性 CDI 患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.